
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Research: New Horizons
Author(s)Kevin Gopal
London, UK-Changes to the law on human embryo research could herald a new era for UK biotech research. The government feared its proposals to allow the cloning of embryos as sources for stem cells for research would be thrown out by the House of Lords-where a powerful body of opinion holds that they represent a slippery slope toward reproductive cloning-but the proposals passed by a surprisingly large majority.
Advertisement
Articles in this issue
about 25 years ago
Earnings: Tough Times Aheadabout 25 years ago
Outbreak: Anthrax Alarmabout 25 years ago
Patents: China on the Genome Mapabout 25 years ago
Privacy, Pediatrics, and Policyabout 25 years ago
Lilly's International Familyabout 25 years ago
Update: Punishment and Reprieveabout 25 years ago
Shortage: Vaccine Worriesabout 25 years ago
Gateway to Japanabout 25 years ago
SurroundedAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5




